secwatch.observer — SEC 8-K summary
======================================

Issuer:     Editas Medicine, Inc. (EDIT)
CIK:        0001650664
Form:       8-K
Filed at:   2023-11-03T23:59:59+00:00
Accession:  0001650664-23-000014
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Editas Medicine Q3 2023 net loss $45.0M; cash $446.4M; EDIT-301 data at ASH
---------------------------------------------------------------------------

- Net loss of $45.0M ($0.55/share) vs $55.7M ($0.81/share) in Q3 2022.
- Collaboration revenue $5.3M vs $42K, driven by Vor Bio Cas9 license upfront payment.
- Cash and securities $446.4M; expected to fund operations into Q3 2025.
- EDIT-301 clinical update from RUBY (SCD) and EdiTHAL (TDT) at ASH Dec 11.
- Appointed Caren Deardorf as first Chief Commercial and Strategy Officer.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1650664/000165066423000014/0001650664-23-000014-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1650664/000165066423000014/edit-20231103.htm
  HTML page:      https://secwatch.observer/filing/0001650664-23-000014

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer